Walleye Capital
NGNE icon

Walleye Capital’s Neurogene NGNE Stock Holding History

Walleye Capital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,102
Closed -$744K – 4775
2025
Q4 		$744K Buy
+36,102
New +$899K ﹤0.01% 2660
2025
Q2 		– Sell
-94,083
Closed -$1.1M – 4866
2025
Q1 		$1.1M Buy
94,083
+19,247
+26% +$334K 0.01% 1891
2024
Q4 		$1.71M Buy
74,836
+30,336
+68% +$1.13M ﹤0.01% 1921
2024
Q3 		$1.87M Sell
44,500
-48,000
-52% -$1.86M ﹤0.01% 2021
2024
Q2 		$3.37M Sell
92,500
-8,362
-8% -$295K 0.01% 1614
2024
Q1 		$5.13M Sell
100,862
-87,639
-46% -$2.93M 0.01% 1276
2023
Q4 		$3.65M Buy
+188,501
New +$2.7M 0.01% 1319
2022
Q2 		– Sell
-708
Closed -$27K – 2602
2022
Q1 		$27K Buy
+708
New +$41.3K ﹤0.01% 1907

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Walleye Capital's NGNE Position: Q1 2026 in Review

Walleye Capital sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 36,102 shares — an estimated $744K sold.

Walleye Capital first reported a position in NGNE in Q1 2022 and held it in 8 quarters. The position peaked at $5.13M in Q1 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Walleye Capital reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 36,102 Neurogene shares in Q1 2026, an estimated $744K.
  • Walleye Capital first reported a position in Neurogene in Q1 2022 and held it in 8 quarters.
  • Walleye Capital's Neurogene position peaked at $5.13M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.